Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HIF2α Inhibitor”

6 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 6 of 6 results

Testing effectiveness (Phase 2)Looking for participantsNCT07049926
What this trial is testing

Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)

Who this might be right for
Renal Cell Carcinoma
Merck Sharp & Dohme LLC 140
Testing effectiveness (Phase 2)Looking for participantsNCT07167329
What this trial is testing

Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL Trial

Who this might be right for
Von Hippel LindauVon Hippel Lindau DiseaseVon Hippel Lindau-Deficient Clear Cell Renal Cell Carcinoma+5 more
José Claudio Casali da Rocha 100
Early research (Phase 1)Active Not RecruitingNCT02974738
What this trial is testing

A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)

Who this might be right for
Advanced Solid TumorsSolid TumorSolid Carcinoma+13 more
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 120
Testing effectiveness (Phase 2)Ended earlyNCT05119335
What this trial is testing

NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma

Who this might be right for
ccRCCClear Cell Renal Cell CarcinomaKidney Cancer+14 more
NiKang Therapeutics, Inc. 120
Early research (Phase 1)Study completedNCT06919991
What this trial is testing

Drug-Drug Interaction Study of Casdatifan in Healthy Adult Participants (ARC-29)

Who this might be right for
Healthy Participants
Arcus Biosciences, Inc. 14
Early research (Phase 1)Active Not RecruitingNCT02293980
What this trial is testing

A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001)

Who this might be right for
ccRCCRCCKidney Cancer+2 more
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 110